Long-term safety of iPS-derived cell therapy for spinal cord injury confirmed

Researchers have confirmed the four-year safety profile of induced pluripotent stem (iPS) cell transplantation for spinal cord injuries. This milestone clears a critical regulatory hurdle, enabling the transition to formal clinical trials to evaluate therapeutic efficacy.